ANAB | AnaptysBio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	38.15 - 40.55
52 Week Range	13.36 - 41.31
Beta	-0.31
Implied Volatility	65.92%
IV Rank	19.68%
Day's Volume	263,291
Average Volume	332,122
Shares Outstanding	30,199,800
Market Cap	1,169,336,256
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-01-26

Valuation
Profitability
Growth
Health
P/E Ratio	-6.10
Forward P/E Ratio	N/A
EPS	-6.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	117
Country	USA
Website	ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ANAB's peers: AADI, ADAG, AGIO, ALVR, DCPH, CRNX, RYTM, KURA, CTMX, ANEB, APRE, ATXS, AVTX, BCYC, CAPR, CDMO, CELC, CLDX, COGT, CORT, CMPX, IDYA, IMNM, KROS, MGTX, MRUS, ACRV, SRRK, STRO, SVRA, TVTX, VCYT, VERA, XENE, XNCR, BLTE, IRON

*Chart delayed

Analyzing fundamentals for ANAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ANAB Fundamentals page.

Watching at ANAB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ANAB Technicals page.